Alpha Cognition Inc. (ACOG)
NASDAQ (CM) NASDAQ (CM) Primary 
Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year?
Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?
Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.31 per share a year ago.
Alpha Cognition Inc. (ACOG) Q3 2025 Earnings Call Transcript
Alpha Cognition Inc. ( ACOG ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Henry Du - VP of Finance & Accounting and Interim CFO Michael McFadden - CEO & Director Lauren D'Angelo - Chief Operating Officer Conference Call Participants Boris Peaker David Storms - Stonegate Capital Partners, Inc., Research Division Presentation Operator Greetings. Welcome to Alpha Cognition's Earnings Conference Call.
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.25 per share a year ago.
Alpha Cognition Inc. (ACOG) Q2 2025 Earnings Call Transcript
Alpha Cognition Inc. (NASDAQ:ACOG ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Henry Du - VP of Finance & Accounting and Interim CFO Lauren D'Angelo - Chief Operating Officer Michael E. McFadden - CEO & Director Conference Call Participants David Joseph Storms - Stonegate Capital Partners, Inc., Research Division Raghuram Selvaraju - H.C.
What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock
Alpha Cognition Inc. (ACOG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross?
Alpha Cognition Inc. (ACOG) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACOG's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity
Zunveyl nearly eliminates the onerous GI and sleep disturbance side effects of gold-standard AChEI drugs used to treat Alzheimer's. With failure of anti-amyloid antibodies and no clear disease-modifying therapies in late-stage development (yet), the $5.5 billion Alzheimer's market is severely underserved and dissatisfied. Lean, experienced commercial team launched Zunveyl in March into the long-term care (LTC) market vertical, which accounts for 32% of Alzheimer's scripts.
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.75 per share a year ago.
Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript
Alpha Cognition Inc. (NASDAQ:ACOG ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Henry Du - Interim Chief Financial Officer Michael McFadden - Chief Executive Officer Lauren D'Angelo - Chief Operating Officer Conference Call Participants Michael Freeman - Raymond James Dave Storms - Stonegate Operator Greetings, and welcome to the Alpha Cognition Earnings Call. At this time, all participants are in a listen-only mode.
